/

Business

Atai is going PUBLIC! Company Rundown and MindMed Comparison

Powered by Restream https://restream.io/ What's up Psychedelic Investors?!? We have some big news for you. Atai Life Sciences will be going public imminently, directly competing with companies like MindMed (MMED / MMEDF / MMQ) and Numinus (NUMI). This will be a catalyst for the entire sector, and I am excited. I will be buying some atai when it goes public, how about you? If you wish to collaborate, send us an email at: thepsychedelicinvestor@gmail.com Music: www.bensound.com DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #AtaiLifeSciences #AtaiIPO #MindMed
Psychedelic Start-Up Atai Life Sciences to Raise $100 Million in IPO, 2nd to List on Nasdaq

Psychedelic Start-Up Atai Life Sciences to Raise $100 Million in IPO, 2nd to List on Nasdaq

Atai Life Sciences is now the second psychedelic company to list on Nasdaq, with plans to raise $100 million for its IPO.

Digital Therapeutics and Psychedelic Medicines || MindMed ‘s SECRET WEAPON?!?

Digital Therapeutics and Psychedelic Medicines || MindMed's SECRET WEAPON?!? MindMed (MMED / MMEDF / MMQ) and Atai's secret weapon lies in the digitalization of psychedelic medicines. MindMed has Albert, their Digital Medicines division, and Atai has their Brain Computer Interface. Instead of doing our usual "This Week In Psychedelic Stocks episode", I decided to discuss the article entitled "Digital Therapeutics: Optimizing Psychedelics Therapies With Next-Generation IP" as it pertains to MindMed and Atai and because there wasn't a lot of interesting news for our usual Psychedelic segment. Why should investors in psychedelic stocks be deeply interested in these technological advancements? According to Jeff Nielson, there's two reasons. 1.Generally, next-generation digital technology (which includes the introduction of AI) is already pioneering a tech revolution in healthcare. 2.Specifically, psychedelics-based therapies are one of the areas of medical treatment that will benefit the most from this technology. I hope you guys found some value in this and I'll keep you posted for more changes! Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! If you wish to collaborate, send us an email at: thepsychedelicinvestor@gmail.com Follow us on social media! 🙌 Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor Music: www.bensound.com Time Stamps: 0:00 - Intro 10:08 - Implications for MindMed and Atai DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed​​ ​#MindmedStock​​ #MMEDNews
Psychedelic Business News Spotlight: April 16, 2021

Psychedelic Business News Spotlight: April 16, 2021

This week in psychedelic business news:psilocybin’s genome sequencing explored, psychedelics meet artificial intelligence, and more.

Psilocybin Trial Treating Depression CRUSHES It [Are We At A Turning Point?]

Results Are OUT! Finally we see that psilocybin is MORE EFFECTIVE in treating depression than the commonly used SSRIS. This study, run by the Imperial College of London is the FIRST MAJOR STUDY directly comparing SSRI’s with psilocybin, the predominant method of treatment. The data was released on the 14th of April. So yes, this psilocybin trial treating depression CRUSHED SSRIS! The study had 59 patients with Major Depressive Disorder, 30 of whom took 2 doses of Psilocybin 3 weeks apart, and 29 of whom took an SSRI, and the results will have MASSIVE IMPLICATIONS throughout the psychedelic investing world. Though the study's primary research objective which was purely by how much depression declined using the Quids SR 16 test, EVERY OTHER MEASUREMENT, such as using other measuring methods, decreases in Suicide ideation and percentage of patients in remission were secondary research objectives. And again, every secondary research objective heavily FAVORED psilocybin. This will be major news for companies like Compass Pathways (CMPS) and MindMed (MMED / MMEDF / MMQ) Link to study: https://www.nejm.org/doi/suppl/10.1056/NEJMoa2032994/suppl_file/nejmoa2032994_appendix.pdf So that's it for This Week in Psychedelic Stocks fellow psychedelic investors! I hope you guys found some value in this and I'll keep you posted for more changes! Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com Music: www.bensound.com https://benzinga.grsm.io/jameshallifa ​... ​ https://benzinga.grsm.io/thepsychedel ​... ​ General thoughts. We've been covering decriminalization and legalization efforts for almost two months now and EVERY WEEK, we see a new state or city starting to understand that psychedelics may be beneficial to society and may be able to treat mental illnesses such as depression, anxiety, ADHD, etc. On top of that, every week, we see study after study releasing promising results on the benefits of psychedelics to treat such mental maladies. If this is not proof that the SHROOM BOOM is real, what is? As more studies are released, it'll only become more clear that psychedelics such as psilocybin, MDMA, DMT, LSD, etc may be able to disrupt a TRILLION dollar industry and us psychedelic investors might as well extract two-fold benefits : a. getting massive returns on investment and b. contributing to make the world a better place. DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed​​​​ ​#psilocybin​​​​ #shroomboom
GH Research Raises $125 Million to Fund DMT Treatment for Depression

GH Research Raises $125 Million to Fund DMT Treatment for Depression

GH Research closed a $125 million Series B financing round to fund the advancement of its 5-MeO-DMT treatment.
psychedelic mushrooms

Silo Wellness Expands Shareholder Base to Europe

Toronto's Silo Wellness is now trading on the German Stock Exchange as demand for psychedelic treatments expands.

Daniel Carcillo’s Psychedelic Startup Wesana Health Raises More Funds, On Track to Go Public

,
Former NHL player Daniel Carcillo's psychedelic startup Wesana Health is preparing to take the company public.

BIG MindMed MDMA Trial, Atai to Compete with Elon’s Neuralink ? (+ Updates on CMPS, MYCO and ENBI)

Hey Psychedelic Investors! There's been so much news this week that we decided to split "This Week In Psychedelic Stocks" in 2 parts. Part Deux: " BIG MindMed MDMA Trial, Atai's to Compete with Tesla's Neuralink (+Updates on CMPS, MYCO and ENBI)" might be a lot more interesting to some of you, however, I would suggest you watch Part I entitled: "HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market?" That is if you are interested in the general developments in the psychedelic industry for this week. In this episode, there's lots of news for the psychedelic industry writ large. We'll start up with three different studies that were released in the first week of April. 1. We'll cover some MindMed News [ MMED / MMEDF recently announced a new MDMA study ] 2. Atai Life Sciences' Computer Brain Interface & their clinical trial to treat Schizophrenia 3. Compass Pathways (CMPS) has amazing new price targets 4. Mydecine (MYCO / MYCOF ) has progressed four new compounds towards clinical trials 5. Entheon's (ENBI / ENTBF) new Genetic Test Kit Updates ​... ​Timestamps: 0:00​ - Intro 1:47 - MindMed's (MMED / MMEDF / MMQ) Announcing New Data on Personalized MDMA Dosing 6:08 - Atai Life Sciences acquires Psyber Inc to develop Brain Computer Interface -enabled digital therapeutics targeting mental health disorder 8:00 - Atai's Subsidiary, Recognify Life Sciences, to Commence Phase 2 clinical study in Cognitive Impairment associated with Schizophrenia 9:07 - Roth Capital Upgrades Compass Pathways (CMPS) price targets & CMPS has scheduled a corporate update 10:32 - Mydecine ( MYCOF / MYCO ) Announces Four New Lead Drug Candidates for Pre-IND Meetings with the FDA & Health Canada to prepare for clinical trials. ( MYCO 001, MYCO 002, MYCO 003 & MYCO 004 ) 13:02 - Entheon Biomedical (ENBI / ENTBF ) has now launched Halugen's Psychedelics' Genetic KIT So that's it for This Week in Psychedelic Stocks fellow psychedelic investors! I hope you guys found some value in this! As our thumbnail titles states: The SHROOM BOOM is REAL! Psychedelics are taking the world by storm and psychedelic inspired companies are releasing news every single day. We'll try to cover most of them but if there's a company you want us to cover more in debt, please let us know in the comments and we'll try to satisfy your demands. Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com Music: www.bensound.com https://benzinga.grsm.io/jameshallifa ​... ​ https://benzinga.grsm.io/thepsychedel DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed​​​​ ​#MMEDStock #CMPS Stock

© 2023 Psychedelic Spotlight. | Owned and operated by PSYC Media Corporation, Inc. a US publicly traded company (OTCPink: PSYC) | All Rights Reserved.